Core Insights - Curaleaf's stock experienced a nearly 10% increase due to positive news regarding cannabidiol (CBD), a nonpsychoactive compound in marijuana, rather than THC, which is known for its psychoactive effects [1][2] Group 1: Clinical Study Findings - A clinical study indicated that CBD may improve withdrawal and relapse conditions in individuals with alcohol use disorder, as reported in the scientific journal Nature [4] - The study involved 166 rodents, with two cohorts receiving synthetic CBD injections, showing milder withdrawal symptoms and a lower risk of relapse compared to the control group [5] Group 2: Implications for CBD - The study's findings are significant as they suggest a potential new therapeutic use for CBD, which could influence governmental perspectives on marijuana-derived substances, given that the study was partially funded by the National Institute on Alcohol Abuse and Alcoholism [6] - Despite CBD not being a major part of Curaleaf's business currently, successful studies like this could lead to a revival of interest and demand for CBD products [7]